Genelux (GNLX) Competitors $2.88 -0.23 (-7.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.95 +0.07 (+2.43%) As of 04/25/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. ZVRA, MREO, ALT, KMDA, ZYBT, SANA, SNDL, ERAS, ORKA, and ORICShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Zevra Therapeutics (ZVRA), Mereo BioPharma Group (MREO), Altimmune (ALT), Kamada (KMDA), Zhengye Biotechnology (ZYBT), Sana Biotechnology (SANA), SNDL (SNDL), Erasca (ERAS), Oruka Therapeutics (ORKA), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Zevra Therapeutics Mereo BioPharma Group Altimmune Kamada Zhengye Biotechnology Sana Biotechnology SNDL Erasca Oruka Therapeutics ORIC Pharmaceuticals Genelux (NASDAQ:GNLX) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Which has preferable earnings and valuation, GNLX or ZVRA? Genelux has higher earnings, but lower revenue than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K12,457.44-$28.30M-$0.96-3.00Zevra Therapeutics$23.61M16.67-$46.05M-$2.24-3.21 Is GNLX or ZVRA more profitable? Genelux has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Genelux's return on equity of -105.05% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Zevra Therapeutics -342.63%-159.54%-51.50% Do analysts prefer GNLX or ZVRA? Genelux currently has a consensus target price of $18.25, indicating a potential upside of 533.68%. Zevra Therapeutics has a consensus target price of $22.29, indicating a potential upside of 209.52%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts clearly believe Genelux is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the MarketBeat Community favor GNLX or ZVRA? Zevra Therapeutics received 20 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 94.74% of users gave Zevra Therapeutics an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes16100.00% Underperform VotesNo VotesZevra TherapeuticsOutperform Votes3694.74% Underperform Votes25.26% Do institutionals and insiders believe in GNLX or ZVRA? 37.3% of Genelux shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor GNLX or ZVRA? In the previous week, Zevra Therapeutics had 5 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Zevra Therapeutics and 1 mentions for Genelux. Genelux's average media sentiment score of 1.87 beat Zevra Therapeutics' score of 1.25 indicating that Genelux is being referred to more favorably in the media. Company Overall Sentiment Genelux Very Positive Zevra Therapeutics Positive Which has more risk and volatility, GNLX or ZVRA? Genelux has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. SummaryGenelux beats Zevra Therapeutics on 12 of the 18 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.66M$6.71B$5.46B$7.81BDividend YieldN/A3.16%5.43%4.26%P/E Ratio-3.037.2322.4318.46Price / Sales12,457.44239.68391.42101.46Price / CashN/A65.8538.1834.62Price / Book3.956.306.684.19Net Income-$28.30M$143.17M$3.22B$248.05M7 Day Performance9.51%8.00%6.25%6.54%1 Month Performance-4.95%-4.01%-2.70%-1.97%1 Year Performance-15.29%-2.24%16.86%4.72% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.9094 of 5 stars$2.88-7.4%$18.25+533.7%-15.3%$99.66M$8,000.00-3.0310ZVRAZevra Therapeutics2.6951 of 5 stars$6.87-3.9%$22.29+224.4%+59.3%$371.78M$23.61M-3.4920News CoveragePositive NewsMREOMereo BioPharma Group2.3421 of 5 stars$2.33+1.3%$7.71+231.1%-8.8%$370.47M$1M-38.8340News CoverageHigh Trading VolumeALTAltimmune2.1536 of 5 stars$4.79+5.3%$20.83+334.9%-30.2%$368.90M$20,000.00-3.0950Positive NewsKMDAKamada3.985 of 5 stars$6.40-1.5%$14.67+129.2%+29.9%$367.87M$160.95M22.86360Short Interest ↓ZYBTZhengye BiotechnologyN/A$7.70-23.5%N/AN/A$363.18M$189.75M0.00278Gap DownHigh Trading VolumeSANASana Biotechnology1.8903 of 5 stars$1.59-3.6%$10.80+579.2%-79.7%$357.79MN/A-1.14380Analyst ForecastSNDLSNDL3.0494 of 5 stars$1.36-2.9%$3.63+166.5%-25.9%$357.38M$920.45M-4.39580Upcoming EarningsERASErasca3.1672 of 5 stars$1.24+6.9%$4.83+289.8%-26.5%$351.25MN/A-1.49120News CoveragePositive NewsGap DownORKAOruka Therapeutics3.0843 of 5 stars$9.30+0.9%$39.86+328.6%N/A$348.20MN/A-1.49N/AORICORIC Pharmaceuticals3.9808 of 5 stars$4.87+2.1%$18.86+287.2%-36.8%$345.90MN/A-2.6880News CoverageGap Down Related Companies and Tools Related Companies Zevra Therapeutics Alternatives Mereo BioPharma Group Alternatives Altimmune Alternatives Kamada Alternatives Zhengye Biotechnology Alternatives Sana Biotechnology Alternatives SNDL Alternatives Erasca Alternatives Oruka Therapeutics Alternatives ORIC Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNLX Stock Free GNLX Stock Alerts